MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia

Bookmark and Share
Published: 9 Dec 2019
Views: 706
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

Dr John Seymour speaks to ecancer at the 2019 ASH meeting in Orlando about the four year analysis of the MURANO trial, which showed a sustained benefit of time-limited venetoclax-rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).

He describes the design of the trial and mentions that this time-limited treatment approach provides good disease control and durable time of treatment for most of these patients.

Dr Seymour states that this updated analysis confirm the progression-free survival and overall survival benefit, along with assessing the sensitivity to subsequent therapy after disease-progression.

This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.